

Min-jiang Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4330367/publications.pdf>

Version: 2024-02-01

47
papers

1,037
citations

471509
17
h-index

477307
29
g-index

59
all docs

59
docs citations

59
times ranked

1709
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 219-227.	1.9	19
2	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1059-1066.	1.9	2
3	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. <i>Thoracic Cancer</i> , 2022, 13, 539-548.	1.9	5
4	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <scp>China</scp>. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	1.9	19
5	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 879554.	2.8	0
6	Prognostic impact of maximum standardized uptake value on 18 F-FDG PET / CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 845-853.	1.9	7
7	Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. <i>Frontiers in Immunology</i> , 2021, 12, 619147.	4.8	18
8	Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events. <i>Thoracic Cancer</i> , 2021, 12, 1814-1823.	1.9	10
9	Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2339-2344.	1.9	6
10	Case report of neurofibromatosis type 1 combined with primary ciliary dyskinesia. <i>Frontiers of Medicine</i> , 2021, , 1.	3.4	2
11	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021, 9, 79.	6.8	36
12	Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. <i>Thoracic Cancer</i> , 2021, , .	1.9	6
13	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	4.8	11
14	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	2.8	14
15	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. <i>Clinical Respiratory Journal</i> , 2020, 14, 1131-1136.	1.6	6
16	Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000823.	4.5	11
17	Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. <i>Thoracic Cancer</i> , 2020, 11, 1955-1962.	1.9	16
18	Patterns of response in metastatic NSCLC during PD-L1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. <i>Thoracic Cancer</i> , 2020, 11, 1068-1075.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Tâ€cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. Journal of Pathology, 2020, 251, 147-159.	4.5	25
20	Renal immuneâ€related adverse events of immune checkpoint inhibitor. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 305-311.	1.1	6
21	Recognition and management of the gastrointestinal and hepatic immuneâ€related adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 95-102.	1.1	6
22	<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>. Cancer Management and Research, 2019, Volume 11, 8191-8200.	1.9	4
23	Realâ€world data on EGFR/ALK gene status and firstâ€line targeted therapy rate in newly diagnosed advanced nonâ€small cell lung cancer patients in Northern China: A prospective observational study. Thoracic Cancer, 2019, 10, 1521-1532.	1.9	18
24	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine, 2019, 42, 304-310.	6.1	51
25	Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. Thoracic Cancer, 2019, 10, 791-798.	1.9	7
26	Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2â€mutant lung cancer. International Journal of Cancer, 2019, 144, 788-801.	5.1	16
27	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. Journal of Clinical Oncology, 2019, 37, e20513-e20513.	1.6	0
28	Prognostic role of circulating tumor cells in patients with <i>EGFR</i>â€mutated or <i>ALK</i>â€rearranged nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 640-645.	1.9	23
29	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncology, 2018, 14, 665-674.	2.4	49
30	Paraneoplastic limbic encephalitis associated with lung cancer. Scientific Reports, 2018, 8, 6792.	3.3	29
31	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer, 2018, 125, 142-149.	2.0	34
32	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. Journal of Thoracic Disease, 2018, 10, 3965-3972.	1.4	9
33	Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. Clinical Cancer Research, 2018, 24, 6066-6077.	7.0	178
34	<i>ALK</i>â€rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report. Thoracic Cancer, 2018, 9, 1078-1081.	1.9	3
35	Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage â€ca non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e20531-e20531.	1.6	1
36	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications, 2017, 8, 823.	12.8	53

#	ARTICLE	IF	CITATIONS
37	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. <i>Oncotarget</i> , 2017, 8, 5861-5873.	1.8	41
38	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. <i>Oncotarget</i> , 2017, 8, 86969-86984.	1.8	5
39	Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. <i>Oncotarget</i> , 2017, 8, 86615-86624.	1.8	32
40	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. <i>Theranostics</i> , 2016, 6, 1232-1243.	10.0	42
41	A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. <i>Oncology Letters</i> , 2016, 11, 2573-2579.	1.8	17
42	Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small cell lung cancer. <i>Respirology</i> , 2016, 21, 519-525.	2.3	61
43	EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1305-1310.	2.3	52
44	Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. <i>PLoS ONE</i> , 2015, 10, e0139144.	2.5	32
45	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19070-e19070.	1.6	0
46	Effect of abundance of EGFR activating mutations and presence of T790M mutation in TKIs-naïve tumor specimen on gefitinib response duration in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19077-e19077.	1.6	1
47	Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib. <i>Chinese Medical Journal</i> , 2013, 126, 2235-41.	2.3	14